Abstract
We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. Interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone- marrow cells after I year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on bone-marrow transformed cells.
| Original language | English |
|---|---|
| Pages (from-to) | 126-128 |
| Number of pages | 3 |
| Journal | American Journal of Hematology |
| Volume | 56 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Oct 1997 |
Fingerprint
Keywords
- Cytogenetics
- Fluorescence in situ hybridization
- Interferon-alpha
- Polycythemia vera
ASJC Scopus subject areas
- Hematology
Cite this
Polycythemia vera treated with recombinant interferon-alpha 2a : Evidence of a selective effect on the malignant clone. / Massaro, Paolo; Foa, Paolo; Pomati, Mauro; LaTargia, Maria Luisa; Iurlo, Alessandra; Clerici, Claudia; Caldiera, Sarah; Fornier, Monica; Maiolo, Anna Teresa.
In: American Journal of Hematology, Vol. 56, No. 2, 10.1997, p. 126-128.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Polycythemia vera treated with recombinant interferon-alpha 2a
T2 - Evidence of a selective effect on the malignant clone
AU - Massaro, Paolo
AU - Foa, Paolo
AU - Pomati, Mauro
AU - LaTargia, Maria Luisa
AU - Iurlo, Alessandra
AU - Clerici, Claudia
AU - Caldiera, Sarah
AU - Fornier, Monica
AU - Maiolo, Anna Teresa
PY - 1997/10
Y1 - 1997/10
N2 - We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. Interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone- marrow cells after I year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on bone-marrow transformed cells.
AB - We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. Interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone- marrow cells after I year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on bone-marrow transformed cells.
KW - Cytogenetics
KW - Fluorescence in situ hybridization
KW - Interferon-alpha
KW - Polycythemia vera
UR - http://www.scopus.com/inward/record.url?scp=0030768429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030768429&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A
DO - 10.1002/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A
M3 - Article
C2 - 9326356
AN - SCOPUS:0030768429
VL - 56
SP - 126
EP - 128
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 2
ER -